Prospective Study on Fat Retention when using the AuraGen 1-2-3 with AuraClens System in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast
Brief description of study
The purpose of this research is to collect data on the amount of fat that is retained in a subject's body over time after surgery with the AuraGen 123 system. The AuraGen 123 system is a US Food and Drug Administration (FDA) cleared (approved) device. During the fat grafting procedure, fat cells and tissue are removed from the stomach or thighs using liposuction procedures. The fat cells and tissue are then injected into the breast. We also want to find out if women who have fat grafting with the AuraGen 123 system are happy with how the breast looks after the procedure.
Clinical Study Identifier: s22-00723
ClinicalTrials.gov Identifier: NCT05258305
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
